Table 4 Univariate and multivariate analysis of variable factors for overall survival and recurrence-free survival
Overall survival | Recurrence-free survival | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||||||||
Variable | No. of patients | Median months (95% CI) | 5-years, % (95% CI) | p-value | p-value | HR | HR 95% CI | Median months (95% CI) | 5-years % (95% CI) | p-value | p-palue | HR | HR 95% CI |
Age | 0.8381 | 0.4263 | |||||||||||
≤ 60 years | 16 | 19 (14–37) | 8.3 (0.6-30.2) | 8 (5–13) | 13.3 (2.2-34.6) | ||||||||
> 60 years | 72 | 25 (18–31) | 12.4 (5.8-21.5) | 8 (6–10) | 5.6 (1.8-12.5) | ||||||||
Gender | 0.6264 | 0.8117 | |||||||||||
Male | 57 | 23 (17–30) | 10.5 (3.9-28.4) | 7 (5–11) | 7.1 (2.3-15.8) | ||||||||
Female | 31 | 24 (15–37) | 14.3 (4.6-29.3) | 9 (6–11) | 6.5 (1.1-18.6) | ||||||||
Primary tumor | 0.1872 | 0.7773 | |||||||||||
Colon | 69 | 19 (16–27) | 8.6 (3.3-17.2) | 8 (6–10) | 5.9 (1.9-13.2) | ||||||||
Rectum | 19 | 33 (23–58) | 23.7 (7.2-45.5) | 7 (4–13) | 10.5 (1.8-28.4) | ||||||||
Node status | 0.8512 | 0.4566 | |||||||||||
Positive | 65 | 25 (19–32) | 11.4 (5.0-2.8) | 8 (6–10) | 6.2 (2.0-13.8) | ||||||||
Negative | 23 | 18 (14–33) | 13.0 (2.6-32.3) | 10 (5–13) | 9.1 (1.6-25.1) | ||||||||
CLM | 0.9861 | 0.2889 | |||||||||||
Synchronous | 22 | 20 (18–35) | 9.1 (1.6-25.1) | 10 (7–13) | 4.5 (0.3-18.9) | ||||||||
Metachronous | 66 | 26 (16–32) | 12.4 (5.4-22.4) | 7 (5–10) | 7.7 (2.8-15.8) | ||||||||
CEA level before RFA | 0.0189 | 0.0325 | 0.0062 | 0.0442 | |||||||||
≤ 100 ng/ml | 51 | 29 (19–37) | 15.3 (6.7-27.0) | 10 (8–12) | 9.8 (3.6-19.7) | ||||||||
> 100 ng/ml | 37 | 15 (11–25) | 6.9 (1.4-19.1) | 1.672 | 1.044-2.678 | 6 (4–7) | 2.8 (0.2-12.4) | 1.637 | 1.013-2.647 | ||||
Maximum size of CLM | 0.0001 | 0.0939 | <0.0001 | 0.0771 | |||||||||
≤ 3 cm | 61 | 30 (23–36) | 15.3 (7.2-26.1) | 10 (8–11) | 9.8 (4.0-18.8) | ||||||||
3-5 cm | 27 | 12 (10–19) | 3.8 (0.3-16.4) | 1.548 | 0.928-2.581 | 5 (4–6) | 0 | 1.600 | 0.950-2.694 | ||||
Number of CLM | <0.0001 | <0.0001 | 0.0093 | 0.0389 | |||||||||
1-3 | 67 | 27 (21–36) | 15.6 (7.8; 25.9) | 8 (7–11) | 9.0 (3.6-17.2) | ||||||||
4-5 | 21 | 12 (10–18) | 0 | 3.128 | 1.771-5.526 | 5 (4–10) | 0 | 1.771 | 1.029-3.048 | ||||
Response to systemic therapy before RFA | <0.0001 | 0.0005 | <0.0001 | <0.0001 | |||||||||
Partial remission | 49 | 37 (32–48) | 21.6 (10.9-34.7) | 11 (10–13) | 12.5 (5.1-23.4) | ||||||||
Stable disease | 13 | 19 (15–25) | 0 | 8 (6–10) | 0 | ||||||||
Progressive disease | 26 | 10 (9–11) | 0 | 5.456 | 2.289-13.005 | 4 () | 0 | 6.458 | 2.644-15.78 | ||||